2023/05/22 10:35

Program - ISFA 2023

(https://www.e-isfa.org/)(https://www.e-isfa.eu/)

Scientific Program(as of May 2023)

Wednesday, May 31, 2023
17h00 – 18h00

General Assembly E-ISFA(by invitation only)

Thursday, June 1, 2023
08h30 – 08h55

Opening Ceremony
Chairs: Bernd Hohenstein, ISFA President (DE), Wolfgang Ramlow, E-ISFA President (DE)
Congress Opening byBernd Hohenstein, ISFA President (DE)
Wolfgang Ramlow, E-ISFA President (DE)
Ulrich Julius, Honorary Congress President E-ISFA (DE)Horst Klinkmann, Honorary Congress President ISFA (DE)09h00 – 10h20

https://www.isfa2023.com/program/

Apheresis around the world I:
Country specific aspects

Lipid disorders and CVD I:
Lipid disorders – it all starts with the measurement

Chairs:Shamanna Iyengar (Bangalore, IN)
Olivier Moranne (Nimes, FR)

Chairs:Patrick Moriarty (Kansas City, US)
Winfried März (Cologne, DE)

 Presentations () Presentations ()Kurt Derfler (Institute ATHOS, Vienna, AT)
Organization and national activities of therapeutic apheresis in Austria

Winfried März (SYNLAB Akademie, DE)
Dyslipidemia – it all starts with a correct measurement

1/10

2023/05/22 10:35

Program - ISFA 2023

Ken Yamaji (Juntendo University, Tokyo, JP)
Organization and national activities of therapeutic apheresis in Japan

Johanna Schachtl-Riess (Medical University of Innsbruck, AT)
Lipoprotein(a) – from genetics to phenotype

Amber Sanchez (University of California San Diego, US)
Organization and national activities of therapeutic apheresis in the USA

Jeffrey Kroon (University of Amsterdam, NL)
Evidence for a strong pro-inflammatory potential of lipoprotein(a)Selected from abstracts:
Nosakhare G. Bazuaye et al. (Igbinedion University Teaching Hospital,
Benin, Nigeria)
Apheresis activities in a low resource country Nigeria: a five years report of asingle center

Patrick Moriarty (University of Kansas Medical Center, Kansas City, US)
Lipoprotein-apheresis and its effect on HDL functionality

10h20 – 10h45

Coffee Break, Exhibition & Poster Viewing

10h45 – 12h05

Apheresis around the world II:
South East Asian perspectives

Registries
Registries as research tools in apheresis

Chairs:
Sasitorn Siritho (Bangkok, TH)
Wolfgang Ramlow (Rostock, DE)

Chairs:Ulrich Julius (Dresden, DE)
Volker Schettler (Goettingen, DE)

 Presentations () Presentations ()Sasitorn Siritho (Bumrungrad International
Hospital, TH)
Systematic review of TPE practices in central
neuroimmunological disorders: evolving concepts
in South East Asia

Christian Schumann (MVZ Kempten, DE)
CACOV – an apheresis registry for severely ill acute COVID
patients

Lu Fiong Hiew (Kuala Lumpur Hospital, MY)
Uniting the world through TPE: SEATPEC challenges

Bernd Hohenstein (Nephrologisches Zentrum VillingenSchwenningen, DE)
The German Long-Covid Apheresis Register – design and firstexperiences

Apherese-Weiterbildung indeutscher Sprache:
Teil 1
 Program part 1 ()Jens Ringel (Potsdam, DE)
Begrüßung
N. N.
Apherese, eine erfolgreiche Geschichte
Uwe H. Wallstab (Wernigerode,DE)
Apherese ist nicht gleich Apherese& potential future collaborations
Nghia Hoang (Military Hospital, Ho Chi Minh,VN)
TPE and its challenges in Vietnam
Dhayalen Krishnan (Kuala Lumpur General
Hospital, MY)
Introduction to SEATPEC, best practices and TPE
guidelines in South East Asia

12h05 – 12h30

Coffee Break, Exhibition & Poster Viewing

12h30 – 13h45

Lunch Symposium(https://www.isfa2023.com/lunchsymposia/)

https://www.isfa2023.com/program/

Wanja Bernhardt (Centre for Hypertension, Kidney andMetabolic diseases, Hanover, DE)
The German Lipoprotein Apheresis Register – a specific analysisof Lp(a) apheresis patients
Selected from abstracts:
Phandee Watanaboonyongcharoen et al. (Chulalongkorn
University, Bangkok, TH)
A multicenter study of safety and incidence of adverse reactions
associated with therapeutic apheresis in Thai patients

Lunch Symposium(https://www.isfa2023.com/lunchsymposia/)

2/10

2023/05/22 10:35

Program - ISFA 2023

13h45 – 14h00

Break

14h00 – 15h15

Apheresis around the world III:
Current updates & issues (from the American
Society for Apheresis – ASFA)

Autoimmune diseases I
Neuroimmune diseases and immunomodulation
Chairs:Apherese-Weiterbildung indeutscher Sprache:
Teil 2Chair:
Bernd Hohenstein (Villingen-Schwenningen, DE)

Dhayalen Krishnan (Kuala Lumpur, MY)
Reinhard Klingel (Cologne, DE)(14h00 – 15h30)

 Presentations () Presentations ()Jens Ringel (Potsdam, DE)

Joseph (Yossi) Schwartz (Moffit Cancer Center,
Florida, US)

Wolfgang Köhler (Leipzig University, DE)
The role of apheresis therapy in MS and NMOSD

Ultima ratio bei LipoproteinstörungenOlivier Moranne (CHU Caremeau Nimes, University
Montpellier, FR)

Apherese mehr als nur Lipidreduktion

Growing variations in collections for further
manufacturing
Betty Doggett (Carter BloodCare, Laird Hill, US)
Vascular access – issues & resolutions
Nicole Aqui (Perelman School of Medicine,
University of Pennsylvania, US)
ASFA Guidelines for Therapeutic Apheresis – 2023

Immunomodulatory effect associated with therapeuticplasmapheresis

 Programm Teil 2 ()N.N.

Jörg Müller (Dresden, DE)
Heparin oder Citrat zur
Antikoagulation

Selected from abstracts:
Miriam Lanska et al. (University Hospital and Faculty of
Medicine, Hradec Kralove, CZ)
Efficacy and safety of long-term immunoadsorption therapy inpatients with myasthenia gravis
Selected from abstracts:
Virginia Athanasiadou et al. (National and Kapodistrial
University of Athens, GR)
Therapeutic Plasmapheresis: A safe and effective periodic
treatment for chronic inflammatory demyelinating
polyneuropathy

15h15 – 15h45

Coffee Break & Poster Viewing

15h45 – 17h30

Apheresis around the world IV
Apheresis therapy in Japan – JSFA Workshop
Chairs:Chairs:Wladimir Szpirt (Copenhagen, DK)

Apherese-Weiterbildung indeutscher Sprache:
Teil 3Ken Yamaji (Tokyo, JP)
Wolfgang Ramlow (Rostock, DE)

Jan Kielstein (Braunschweig, DE)(16h00 – 17h45)

 Presentations () Programm Teil 3 ()

 Presentations ()Jan Stange (University Medical Center Rostock, DE)

Schwester Anja Ramlow (Rostock,

Ken Yamaj (Juntendo University, Tokyo, JP)
Updated Topics in PE, DFPP and plasma adsorption

Recent developments in the field of extracorporeal albumin
detoxification (ECAD) for liver support

DE)
Pflegerische Aspekte in derusing the membrane separation
Shuzo Kobayashi (Shonan Kamakura General

Gerd Klinkmann (University Medical Center Rostock,
Department of Anesthesiology and Intensive Care Medicine,

Hospital, Kanagawa, JP)A novel LDL/fibrinogen apheresis ‘Rheocarna’ forDE)
Extracorporeal immune cell therapy in sepsis

patients with chronic limb-threatening ischemia
https://www.isfa2023.com/program/

Apheresis in critical care medicine

Apheresebehandlung vonLong/Post-Covid Patienten
Volker Witt (Vienna, AT)
Pflegerische Aspekte in der
Apheresebehandlung von Kindern
3/10

2023/05/22 10:35

Program - ISFA 2023

Tomoki Tanaka (Shiga University, Shiga, JP)

Steffen Mitzner (University Medical Center Rostock, DE)

Jens Ringel (Potsdam, DE)

The development history of Toraymyxin and the

Cytokine adsorption in sepsis and septic shock – still under

Vorstellung der E-ISFA

update of clinical data of PMX-DHP

debateMakoto Naganuma (Kansai Medical University,
Osaka, JP)
Developments and future perspective of apheresis
therapy for inflammatory bowel disease

Amber Sanchez (University of California San Diego, US)
How to combine multiple extracorporeal systems in critical careJens Ringel (Potsdam, DE)
Verabschiedung

Sascha David (Zurich University Hospital, CH)
TPE in septic shock: to remove and replace

17h30 – 19h30

Welcome Reception & Poster Session

Friday, June 2, 2023
08h30 – 09h50

Apheresis around the world V:
Country specific aspects

Guest workshop:
Association of German Dialysis Centers (DN e. V.)

09h00 – 12h00

Chairs:Amber Sanchez (San Diego, US)

Chairs:Georg Schlieper (Hanover, DE)deutscher Sprache:

Kurt Derfler (Vienna, AT)

Wladimir Szpirt (Copenhagen, DK) Presentations () Presentations ()Shamanna Iyengar (Manipal Academy ofGeorg Schlieper (Dialysis Centre Hanover, DE)

Schwester Anja Ramlow (Rostock,
DE)

Higher Education, IN)
On the way to establish a lipid apheresis program

Is there a role for immunoadsorption in Post Covid?

Begrüßung

Volker Schettler (Center of Nephrology, Dialysis andGruppenarbeit an den

Apheresis, Göttingen, DE)
The German Lipoprotein Apheresis Registry (GLAR) – Summary ofverschiedenen Maschinen mit
Erfahrungsaustausch unter den

the tenth annual report

Pflegenden zu je 150 min(https://www.isfa2023.com/apherese-in India by Lipid Association of India (LAI)
Ahmad AlSaraf (Sabah AlAhmad Cardiac
Center, KW)
LDL apheresis in homozygous familial
hypercholesterolemia in Kuwait
Luigi Vernaglione (Perrino Hospital, Brindisi, IT)

Jan Kielstein (Braunschweig Hospital, DE)
From sepsis to COVID – apheresis therapy in critical care
medicine

Cross sectional analysis of apheretical therapies in
Italy

Apherese-Weiterbildung in Anwenderworkshop Teil 1 ()Jens Ringel (Potsdam, DE)

weiterbildung/)(unter Beteiligung derMedizinprodukte-Hersteller)(_wp_link_placeholder)

Olivier Moranne (CHU Caremeau Nimes,
University Montpellier, FR)
Organization and national activities of therapeutic
apheresis in France
09h50 – 10h20

Coffee Break, Exhibition & Poster Viewing

10h20 – 12h10

COVID-19 I:

Lipid disorders and CVD II:

Apheresis in COVID-19 and its complications

Apheresis targeting microcirculation and inflammation

https://www.isfa2023.com/program/

4/10

2023/05/22 10:35

Program - ISFA 2023

Chairs:Julia Weinmann-Menke (Mainz, DE)

Chairs:Luigi Vernaglione (Brindisi, IT)

Bernd Hohenstein (Villingen-Schwenningen, DE)
 Presentations ()Wanja Bernhardt (Hanover, DE)
 Presentations ()Carmen Scheibenbogen (Charité –Luigi Vernaglione (Perrino Hospital, Brindisi, IT)

Universitätsmedizin Berlin, DE)
Long-term consequences of COVID and current
therapeutic perspectives

Apheresis to improve rheology – indications and results

Beate Jäger (DE)Long COVID – why apheresis therapy could makethe difference
Harald Matthes (Havelhöhe Community
Hospital, Berlin, DE)
Is apheresis therapy an option forneuroinflammatory Post-vaccination syndrome?
Panel discussion – pro and contra

12h10 – 12h30

Double filtration plasmapheresis (DFPP) to improvemicrocirculation
Jan Torzewski (Allgäu Hospital Network, Immenstadt, DE)
CRP – from laboratory parameter to key player of inflammation
Selected from abstracts:
Rosita Bihariesingh et al. (Academic Hospital Paramaribo
Suriname)First-in-Man: Plasmapheresis with a novel blood separation
device in hypertriglyceridemia and acute pancreatitis
Selected from abstracts:
Mohamed Sedky et al. (Kuwait Central Blood Bank)A fifteen-years analysis of therapeutic apheresis practices instate of Kuwait

Lunch Break, Exhibition & Poster Viewing

12h30 – 13h45

Lunch Symposium(https://www.isfa2023.com/lunchsymposia/)

13h45 – 14h00

Lunch Break, Exhibition & Poster Viewing

14h00 – 15h20

COVID-19 II:
Treatment approaches in COVID
and its consequences
Chairs:Yoshihiro Endo (Otsu, Shiga, JP)
Steffen Mitzner (Rostock, DE)
 Presentations ()https://www.isfa2023.com/program/

Dusit Lumlertgul (Faculty of Medicine, Chiang Mai, TH)

New guidelines anddevelopments:
Technical regulations and

Lipid disorders and CVD III:
Workshop German Lipid League

developments

Chairs:Oliver Weingärtner (Jena, DE)
Volker Schettler (Goettingen, DE)

Chairs:Victoria Weber (Krems, AT)
Andre Kaplan (Plainvile, US)

Wladimir M. Szpirt (Rigshospitalet,
Copenhagen, DK)
Plasma exchange utilizing Presentations ()convalescent plasma in severe COVID
patients

Relevance of sufficient clinical safety
and performance data to maintain CE
mark of apheresis devices

Uwe H. Wallstab (mdXperts GmbH,
Cologne, DE)

 Presentations ()13h00 – 15h30
Apherese-Weiterbildung indeutscher Sprache: Anwenderworkshop Teil 2 ()Oliver Weingärtner (University
Hospital Jena, DE)
A nationwide initiative to reach lipid
targets

5/10

2023/05/22 10:35

Program - ISFA 2023

Sebastian Koball (University
Medical Center Rostock, DE)

Viktoria Weber (Danube University
Krems, AT)

Anja Vogt (Ludwig Maximilians
University Hospital, Munich, DE)

How to evaluate apheresis efficacy inpatients suffering from Long COVID?

Influence of the column surface on
therapeutic apheresis – an old issue
but new developments are rising

Novel lipid lowerting medications –current status and future perspectives

Gunnar Bücker (Nephrology grouppractice, Osnabrück, DE)
First clinical results after HELP
apheresis in Long COVID Syndrome
Julia Weinmann-Menke(Universitätsmedizin Mainz, DE)
Removal of circulating antibodies toadenoassociated virus vectors byimmunoadsoption

Selected from abstracts:
Andrew Aswani et al. (Santersus
AG, CH)
Safety and performance of the
NucleoCapture®Column for selective
cfDNA/NETs apheresis in patients with

Ulrich Julius (University Hospital
Dresden, DE)
Cardiovascular events before andduring apheresis treatment – adetailed analysis for vascular regions

sepsisSelected from abstracts:
Kensuke Owari et al. (TAGCyx
Biotechnologies, Inc., Tokyo, JP)
Development of next generation
apheresis using artificial base DNA
Aptamer

15h20 – 15h45

Coffee Break, Exhibition & Poster Viewing

15h45 – 17h30

Lipid disorders and CVD IV:
Treatment modalities in clinial practice

Autoimmune diseases II:
Apheresis in rheumatologic and inflammatory bowel disease

Apheresis Service and Education(in English language)

Chairs:Mariko Harada-Shiba (Osaka, JP)

Chairs:Ken Yamaji (Tokyo, JP)

Chairs:
Betty Doggett (Laird Hill, US)

Tiziana Sampietro (Pisa, IT)

Harald Matthes (Berlin, DE)

N. N.

 Presentations () Presentations () Speakers ()Wanja Bernhardt (Dialysis Centre Hanover, DE)
Long-term experience of Lp(a) apheresis in
outpatient care

Andreas Kronbichler (Medical University Innsbruck, AT)
Apheresis therapy in autoimmune vasculitides – PEXIVAS is not
the end

Tiziana Sampietro (National Research Council
Institute of Clinical Physiology, Pisa, IT)
The role of lipoprotein apheresis on
hypercholesterolemia and Lp(a) – the Pisa
experience
Ulrich Julius (University Hospital Dresden, DE)
Comparison of the plasma lipoprotein apheresis
systems MONET and Lipidfiltration from Diamed vs.
the whole blood apheresis system DALI in thetreatment of patients with cardiovascular disease
and severe dyslipidemia
https://www.isfa2023.com/program/

Yoshihiro Endo (Shiga University of Medical Science, Otsu,
JP)
Novel hemo-adsorbent for ulcerative colitis in Japan
Makoto Naganuma (Keio University School of Medicine,Tokyo, JP)
Recent trends of apheresis treatment for inflammatory bowel
diseaseKen Yamaji (Juntendo University, Tokyo, JP)
Is apheresis therapy still an option in rheumatic diseases?

6/10

2023/05/22 10:35

Program - ISFA 2023

Jannecke Mulder (NL)
Quality of life in Dutch hoFH patients
Mariko Harada-Shiba (National Cerebral andCardiovascular Center, Osaka, JP)

Selected from abstracts:
Natalia Jarzebska (University Hospital Dresden)
Apheresis treatment leads to increased levels of circulating
neutrophil extracellular traps

Development of novel drug for primarychylomicronemia by using antisense
18h30 – 23h00

Congress Dinner

Saturday, June 3, 2023
08h30 – 10h15

Autoimmune diseases III
Apheresis for renal diseases

Lipids and CVD V:
Pleiotropic and other expected windfall gains

Chairs:Andreas Kronbichler (Innsbruck, AT)

Chairs:
Dursit Lumlertgul (Chiang Mai, TH)

Wladimir Szpirt (Copenhagen, DK)

N. N.

 Presentations () Presentations ()Lionel Rostaing (CHU Grenoble Alpes, Grenoble, FR)
Apheresis and desensitization before kidney transplantation

Grit Waitz (BioArtProducts, Rostock, DE)
Cardiometabolic risk assessment – the impact of comorbidities

Benjamin Savenkoff (CHR Metz-Thionville, FR)
The role of apheresis therapy in glomerulopathies

Mariko Harada-Shiba (National Cerebral and Cardiovascular Center,
Osaka, JP)
Lipoprotein apheresis for the treatment of familial hypercholesterolemia in

Vladimir Kuklin (Bruggemann) (Ahus University Hospital, Lorenskog, NO)
Influence of therapeutic plasma exchange treatment on early survival of septic
patients: a systematic review and meta-analysis

Japan

Wladimir Szpirt (Rigshospitalet, Copenhagen, DK)
An evolution in treatment of anti GBM nephritis – plasma exchange or
imlifidase?
Selected from abstracts:
Haruna Yoshida et al. (Osaka City General Hospital)
Selective plasma exchange in critical care
Selected from abstracts:
Noemi Elisabeth Ginthör et al. (Medical University of Graz, AT)
Evaluation of iron deficiency and mechanisms of potential iron loss in patients
undergoing immunoadsorption

Takafumi Ito (JP)
Efficacy and safety of LDL apheresis for the treatment of cholesterol crystal
embolism
Selected from abstracts:
Lena Jochheim et al. (University Hospital Dresden, DE)
Actual situation at the Dresden Lipoprotein Apheresis in 2023
Selected from abstracts:
Volker Schettler et al. (German Center for Neurodegenerative Diseases(DZNE) Goettingen, DE)
Effective exosomes reduction in hypercholesterinemic patients suffering fromcardiovascular diseases by lipoprotein apheresis: exosomes pheresis
Selected from abstracts:
Romy Walther (University Hospital Dresden, DE)
Prognostic value of plasma lipidome for determining the risk of cardiovascular
events in patients with lipoprotein apheresis

https://www.isfa2023.com/program/

7/10

2023/05/22 10:35

Program - ISFA 2023

10h15 – 10h45

Coffee Break, Exhibition & Poster Viewing

10h45 – 12h30

Future perspectives of apheresis therapy
The future perspectives of apheresis

Pediatric apheresis
Apheresis in children and adolescent patients

Chairs:Bernd Hohenstein (Villingen-Schwenningen, DE)
Wolfgang Ramlow (Rostock, DE)

Chairs:Julia Thumfart (Berlin, DE)
Volker Witt (Vienna, AT)

 Presentations () Presentations ()Patrick Moriarty (University of Kansas Medical Center, Kansas City, US)

Wolfgang Ries (Diako Hospital Flensburg, DE)

Future perspectives in apheresis therapy – lipoprotein apheresis

Severe chronic fatigue syndrome (ME/CFS) in children – when isimmunoadsorption justified?

Jan Kielstein (Braunschweig Hospital, DE)
Future perspectives in apheresis therapy – critical care medicine
Lionel Rostaing (CHU Grenoble Alpes, Grenoble, FR)
Future perspectives in apheresis therapy – renal diseases and transplantation
Reinhard Klingel (Apheresis Research Institute, Cologne, DE)
Future perspectives in apheresis therapy – immune-mediated conditions

Julia Thumfart (Charité – Universitätsmedizin Berlin, DE)
Apheresis therapy for pediatric neurological diseases – a German perspective
Volker Witt (Paediatric Hospital “St. Anna”, Vienna, AT)
ECP in children and young adults – special needs
Selected from abstracts:
Claudia Ootjers et al. (Leiden University Medical Centre)
Erythrocytapheresis prior to allogeneic stem cell transplantation in children
with sickle cell disease is a safe and efficient method to lower sickle
haemoglobin
Panel discussion:
Particularities in pediatric apheresis

12h30 – 13h00
13h00

Closing Ceremony & Awards Presentation
FarewellThis project is co-financed by the European Regional Development Fund (ERDF).

https://www.isfa2023.com/program/

8/10

2023/05/22 10:35

Program - ISFA 2023

Newsletter
ISFA 2023 Newsletter:
Enter your e-mail address

Subscribe
After subscribing you will receive an email to confirm your subscription. Please also check the spam folder.

Important Dates
March 31, 2023
Extended Abstract Submission Deadline
March 31, 2023
Deadline Early Registration Fee
May 25, 2023
Deadline Standard Registration Fee
June 1 – 3, 2023
Joint ISFA – E-ISFA Congress in Berlin

Certifications

COMPLIANT
Submitted for certification to the Berlin State Medical Association

Certifications
Organizer
https://www.isfa2023.com/program/

9/10

2023/05/22 10:35

Program - ISFA 2023

International Society for Apheresis – European GroupInternational Society For Apheresis

Schliemannstr. 2
18059 Rostock, Germany

ISFA Headquarters
Shiga University of Medical Science info@e-isfa.eu(mailto:info@e-isfa.eu)
 www.e-isfa.eu(https://www.e-isfa.eu)

Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan isfa@belle.shiga-med.ac.jp(mailto:isfa@belle.shiga-med.ac.jp)
 www.e-isfa.org(https://www.e-isfa.org/)

Congress Office
K.I.T. Group GmbH Dresden
Anja Binning
Bautzner Str. 117–119
01099 Dresden, Germany +49 351 65573135
 info@isfa2023.com(mailto:info@isfa2023.com)
 www.kit-group.org(https://www.kit-group.org)

 Imprint(https://www.isfa2023.com/imprint/)  Disclaimer(https://www.isfa2023.com/disclaimer/)  Privacy Statement(https://www.isfa2023.com/privacy-statement/)
 2022 K.I.T. Group GmbH Dresden(https://www.kit-group.org)  Photo Credits(https://www.isfa2023.com/photo-credits/)

https://www.isfa2023.com/program/

10/10